Marcio Santos da Natividade, Erick Soares Lisboa, Erika Aragão, Caroline Tianeze de Castro, Rafael Damasceno de Barros, Marcos Pereira, Samilly Silva Miranda, Luís Eugênio Souza, Naomar de Almeida-Filho
{"title":"Comparative Analysis of the Average Recommendation Time for the Incorporation of Biological Drugs for Cancer and Rheumatoid Arthritis.","authors":"Marcio Santos da Natividade, Erick Soares Lisboa, Erika Aragão, Caroline Tianeze de Castro, Rafael Damasceno de Barros, Marcos Pereira, Samilly Silva Miranda, Luís Eugênio Souza, Naomar de Almeida-Filho","doi":"10.2147/JMDH.S532154","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the average time between the registration of a biological drug and its recommendation for incorporation for rheumatoid arthritis (RA) and cancer (CA) at national and international levels.</p><p><strong>Methods: </strong>This retrospective, comparative study analyzed the time taken to incorporate biological drugs recommended by National Commission for the Incorporation of Technologies (CONITEC) in the Brazilian Unified Health System(SUS) for RA and CA from January 1, 2012, to March 28, 2024. The incorporation time in Brazil was compared to that of regulatory bodies in England and Australia for the same treatments. Kaplan-Meier curves and the Log rank test were used to estimate time differences between countries.</p><p><strong>Results: </strong>In Brazil, biological drugs for RA took an average of 2,019 days from the National Health Surveillance Agency (ANVISA) approval to CONITEC's incorporation recommendation. In England, the averages were 1,242 days for RA and 1,683 for CA, while in Australia, it was 744 days for RA and 1,315 for CA. Australia incorporated drugs faster than both England and Brazil.</p><p><strong>Conclusion: </strong>The lengthy process in Brazil for incorporating biological technologies for RA and CA may hinder access, delaying treatment for many patients. This barrier is particularly significant for low-income individuals who rely exclusively on the SUS.</p>","PeriodicalId":16357,"journal":{"name":"Journal of Multidisciplinary Healthcare","volume":"19 ","pages":"532154"},"PeriodicalIF":2.4000,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136709/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Multidisciplinary Healthcare","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JMDH.S532154","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To compare the average time between the registration of a biological drug and its recommendation for incorporation for rheumatoid arthritis (RA) and cancer (CA) at national and international levels.
Methods: This retrospective, comparative study analyzed the time taken to incorporate biological drugs recommended by National Commission for the Incorporation of Technologies (CONITEC) in the Brazilian Unified Health System(SUS) for RA and CA from January 1, 2012, to March 28, 2024. The incorporation time in Brazil was compared to that of regulatory bodies in England and Australia for the same treatments. Kaplan-Meier curves and the Log rank test were used to estimate time differences between countries.
Results: In Brazil, biological drugs for RA took an average of 2,019 days from the National Health Surveillance Agency (ANVISA) approval to CONITEC's incorporation recommendation. In England, the averages were 1,242 days for RA and 1,683 for CA, while in Australia, it was 744 days for RA and 1,315 for CA. Australia incorporated drugs faster than both England and Brazil.
Conclusion: The lengthy process in Brazil for incorporating biological technologies for RA and CA may hinder access, delaying treatment for many patients. This barrier is particularly significant for low-income individuals who rely exclusively on the SUS.
期刊介绍：
The Journal of Multidisciplinary Healthcare (JMDH) aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates or reports the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and we welcome submissions from practitioners at all levels and from all over the world. Good healthcare is not bounded by person, place or time and the journal aims to reflect this. The JMDH is published as an open-access journal to allow this wide range of practical, patient relevant research to be immediately available to practitioners who can access and use it immediately upon publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
